Tech Company Financing Transactions
BioSenic Funding Round
On 2/2/2024, BioSenic landed $5.4 million in funding from private investors.
Transaction Overview
Company Name
Announced On
2/2/2024
Transaction Type
Venture Equity
Amount
$5,400,000
Round
Undisclosed
Investors
Proceeds Purpose
BioSenic intends to use the net proceeds of the placement, together with other sources, to prepare for an IND application with FDA for the Phase 3 clinical study with oral arsenic trioxide (OATO) in the first-line treatment of chronic graft-versus-host disease (cGvHD).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Rue Granbonpré 11 -- Bâtiment H (bte 24)
Mont-St-Guibert, 1435
Belgium
Mont-St-Guibert, 1435
Belgium
Phone
Website
Email Address
Overview
BioSenic is an innovative company with the objective of addressing important unmet medical needs in the areas of innate immunity, inflammation and organ/function repair. Our expertise is focused on cell therapy and the therapeutic use of arsenic trioxide (As2O3). BioSenic aims to become a leading company in the field of regenerative and immune medicine by developing innovative products for and autoimmune and inflammatory diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
François Rieger
Chief Marketing Officer
Lieven Huysse
Chief Scientific Officer
Carole Nicco
Browse more venture capital transactions:
Prev: 2/2/2024: gamma. venture capital transaction
Next: 2/2/2024: Myavana venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to document all VC transactions involving tech companies. VC transactions reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs